Hillmen P - Search Results

1

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.

Hale G, Rebello P, Brettman LR, Fegan C, Kennedy B, Kimby E, Leach M, Lundin J, Mellstedt H, Moreton P, Rawstron AC, Waldmann H, Osterborg A, Hillmen P. Hale G, et al. Among authors: hillmen p. Blood. 2004 Aug 15;104(4):948-55. doi: 10.1182/blood-2004-02-0593. Epub 2004 Apr 15. Blood. 2004. PMID: 15090452 Free article. Clinical Trial.

2

The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment.

Rawstron AC, Rollinson SJ, Richards S, Short MA, English A, Morgan GJ, Hale G, Hillmen P. Rawstron AC, et al. Among authors: hillmen p. Br J Haematol. 1999 Oct;107(1):148-53. doi: 10.1046/j.1365-2141.1999.01676.x. Br J Haematol. 1999. PMID: 10520035 Free article.

3

Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria.

Richards SJ, Rawstron AC, Hillmen P. Richards SJ, et al. Among authors: hillmen p. Cytometry. 2000 Aug 15;42(4):223-33. Cytometry. 2000. PMID: 10934341 Review.

4

Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy.

Rawstron AC, Kennedy B, Evans PA, Davies FE, Richards SJ, Haynes AP, Russell NH, Hale G, Morgan GJ, Jack AS, Hillmen P. Rawstron AC, et al. Among authors: hillmen p. Blood. 2001 Jul 1;98(1):29-35. doi: 10.1182/blood.v98.1.29. Blood. 2001. PMID: 11418459 Free article.

5

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia.

Kennedy B, Rawstron A, Carter C, Ryan M, Speed K, Lucas G, Hillmen P. Kennedy B, et al. Among authors: hillmen p. Blood. 2002 Mar 15;99(6):2245-7. doi: 10.1182/blood.v99.6.2245. Blood. 2002. PMID: 11877305 Free article. Clinical Trial.

6

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR. Keating MJ, et al. Among authors: hillmen p. Blood. 2002 May 15;99(10):3554-61. doi: 10.1182/blood.v99.10.3554. Blood. 2002. PMID: 11986207 Free article. Clinical Trial.

7

Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts.

Rawstron AC, Green MJ, Kuzmicki A, Kennedy B, Fenton JA, Evans PA, O'Connor SJ, Richards SJ, Morgan GJ, Jack AS, Hillmen P. Rawstron AC, et al. Among authors: hillmen p. Blood. 2002 Jul 15;100(2):635-9. doi: 10.1182/blood.v100.2.635. Blood. 2002. PMID: 12091358 Free article.

8

Immunological effects and safe administration of alemtuzumab (MabCampath) in advanced B-cLL.

Kennedy B, Hillmen P. Kennedy B, et al. Among authors: hillmen p. Med Oncol. 2002;19 Suppl:S49-55. doi: 10.1385/mo:19:2s:s49. Med Oncol. 2002. PMID: 12180492 Review.

9

Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion.

Rawstron AC, Yuille MR, Fuller J, Cullen M, Kennedy B, Richards SJ, Jack AS, Matutes E, Catovsky D, Hillmen P, Houlston RS. Rawstron AC, et al. Among authors: hillmen p. Blood. 2002 Oct 1;100(7):2289-90. doi: 10.1182/blood-2002-03-0892. Blood. 2002. PMID: 12239136 Free article.

10

Alemtuzumab therapy in B-cell lymphoproliferative disorders.

Moreton P, Hillmen P. Moreton P, et al. Among authors: hillmen p. Semin Oncol. 2003 Aug;30(4):493-501. doi: 10.1016/s0093-7754(03)00253-7. Semin Oncol. 2003. PMID: 12939718 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

290 results

Search Page

Filters